Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial

Trillsch, Fabian; Mahner, Sven; Hilpert, Felix; Davies, Lucy; García‐Martínez, Elena; Kristensen, Gunnar; Savarese, Antonella; Vuylsteke, Peter; Los, Maartje; Zagouri, Flora; Gladieff, Laurence; Sehouli, Jalid; Lee, Chee Khoon; Gebski, Val; Pujade-Lauraine, Éric

doi:10.1093/annonc/mdw236

Cited by 31 publications

(11 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on previous studies, optimal debulking was defined as a maximum diameter of residual tumor after surgery of ≤2 cm 32 , 33 . Patients were defined as platinum-resistant if the disease progressed within 6 months after completing first-line platinum-based chemotherapy, while all other patients were defined as platinum-sensitive 34 . PNI was calculated according to the following formula: serum albumin (g/L) + 0.005 × lymphocyte count (per mm 3 ) in the peripheral blood 11 .…”

Section: Methodsmentioning

confidence: 99%

Preoperative prognostic nutritional index is a powerful predictor of prognosis in patients with stage III ovarian cancer

Zhang

Liang

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Many established inflammation- and nutrition-related factors have been investigated as potential independent prognostic factors in various cancers, including the C-reactive protein/albumin ratio (CAR), lymphocyte/monocyte ratio (LMR), modified Glasgow prognostic score (mGPS), body mass index (BMI), and prognostic nutritional index (PNI). This study was performed to estimate the prognostic value of these factors in predicting survival and platinum resistance in ovarian cancer (OC), especially according to stage. Kaplan-Meier and multivariate analyses were performed to plot the survival curve and determine the independent prognostic factors. Additionally, the area under the receiver operating characteristic curve (AUC) was used to predict platinum resistance and prognosis by comparing the predictive ability of PNI and cancer antigen (CA)-125. In all patients, decreased PNI was significantly associated with platinum resistance and poor overall survival (OS) and progression-free survival (PFS). Regarding tumor stage, decreased PNI was significantly associated with poor PFS and OS only in stage III OC. Furthermore, the PNI also showed a significantly higher AUC value than CA-125 for predicting mortality and platinum resistance in all OC patients, but not in stage III patients. In conclusion, decreased PNI is a powerful predictor of a poor prognosis in OC, and especially for stage III cases.

show abstract

Section: Methodsmentioning

confidence: 99%

Preoperative prognostic nutritional index is a powerful predictor of prognosis in patients with stage III ovarian cancer

Zhang

Liang

et al. 2017

Sci Rep

View full text Add to dashboard Cite

show abstract

“…However, development of recurrent or drug‐resistant disease in most women necessitates the use of alternative strategies, such as dose‐dense therapy, aimed at improving both progression‐free survival and overall survival . To address the unmet need for novel strategies that deliver improved survival benefits, targeted agents are increasingly seen as an option for combination treatment with conventional cytotoxic chemotherapy …”

mentioning

confidence: 99%

“…(2)(3)(4)(5) To address the unmet need for novel strategies that deliver improved survival benefits, targeted agents are increasingly seen as an option for combination treatment with conventional cytotoxic chemotherapy. (6) Veliparib (ABT-888) is a potent, orally bioavailable poly (ADP-ribose) polymerase (PARP)-1/2 inhibitor that may increase the efficacy of chemotherapeutic regimens by delaying DNA repair after chemotherapy-induced damage. (7) In preclinical models, veliparib enhanced the activity of cisplatin, carboplatin and cyclophosphamide, whereas cell lines that quickly develop resistance to taxanes and carboplatin retained their sensitivity to veliparib, thus supporting the candidacy of this agent for the treatment of platinum-resistant or taxaneresistant ovarian cancer.…”

mentioning

confidence: 99%

Phase 1 study of veliparib with carboplatin and weekly paclitaxel in Japanese patients with newly diagnosed ovarian cancer

et al. 2017

View full text Add to dashboard Cite

This phase 1, open‐label, dose‐escalation study was conducted to determine the safety, tolerability, pharmacokinetics and preliminary efficacy of veliparib with carboplatin and weekly paclitaxel in Japanese women with newly diagnosed, advanced ovarian cancer. Patients received veliparib at 100 or 150 mg b.i.d. on days 1–21 with carboplatin (area under the concentration–time curve 6 mg/mL•min) on day 1 and paclitaxel 80 mg/m2 on days 1, 8 and 15 every 3 weeks for up to 6 21‐day cycles. Dose escalation followed a 3 + 3 design to determine dose‐limiting toxicities, maximum tolerated dose and the recommended phase 2 dose. Nine patients (median age 62 [range 27–72] years) received a median of 5 (range 3–6) cycles of treatment (3 at 100 mg, 6 at 150 mg). There were no dose‐limiting toxicities. The most common adverse events of any grade were neutropenia (100%), alopecia (89%), peripheral sensory neuropathy (78%), and anemia, nausea and malaise (67% each). Grade 3 or 4 adverse events were associated with myelosuppression. Pharmacokinetics of carboplatin/paclitaxel were similar at both veliparib doses. Response, assessed in five patients, was partial in four and complete in one (objective response rate 100%). The response could not be assessed in four patients who had no measurable disease at baseline. The recommended phase 2 dose of veliparib, when combined with carboplatin/paclitaxel, is 150 mg b.i.d. Findings from this phase 1 trial demonstrate the tolerability and safety of veliparib with carboplatin/paclitaxel, a regimen with potential clinical benefit in Japanese women with ovarian cancer.

show abstract

“…The AURELIA trial, an exploratory analysis of the AUR-ELIA trial, and real-world evidence demonstrate the benefit of bevacizumab in PR-ROC settings [19][20][21]. They also support the panel recommendations on the addition of bevacizumab to single-agent chemotherapy (liposomal doxorubicin, topotecan, or paclitaxel) in recurrent ovarian cancer settings.…”

Section: Platinum-sensitive Recurrent Ovarian Cancer (Ps-roc) Settingsmentioning

confidence: 63%

“…Further analyses within the SPR and PPR subgroups revealed that the addition of bevacizumab conferred a numerically more pronounced PFS benefit in the SPR subgroup (HR 0.30) than in the PPR subgroup (HR 0.55; treatment-subgroup interaction p = 0.07). Similarly, for OS, a non-significant direction of effect was observed (p for interaction 0.18) [21].…”

Section: Platinum-sensitive Recurrent Ovarian Cancer (Ps-roc) Settingsmentioning

confidence: 91%

Use of Bevacizumab in Advanced Ovarian Cancer: Consensus from an Expert Panel Oncologists

Advani

Doval

Koppikar

et al. 2021

Indian J Gynecol Oncolog

View full text Add to dashboard Cite

Purpose To discuss and reach a consensus on the use of bevacizumab in women with advanced ovarian cancer in Indian settings. Methods An advisory board meeting comprising Indian oncologists was convened to review key literature available on the role of bevacizumab in the management of advanced ovarian cancer. Key recommendations were devised via consensus by the expert panel based on the analysis of available scientific evidence and clinical experience. Results The expert panel recommends the use of bevacizumab in patients with advanced ovarian cancer in first-line settings, as well as in recurrent settings. Conclusion This document summarizes key discussion points and recommendations provided by the advisory panel, which helps guide clinicians on the use of bevacizumab for managing advanced ovarian cancer in the Indian setting. It also acts as a pragmatic tool to assist clinicians in making appropriate treatment decisions with respect to advanced ovarian cancer.

show abstract

Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial

Cited by 31 publications

References 12 publications

Preoperative prognostic nutritional index is a powerful predictor of prognosis in patients with stage III ovarian cancer

Preoperative prognostic nutritional index is a powerful predictor of prognosis in patients with stage III ovarian cancer

Phase 1 study of veliparib with carboplatin and weekly paclitaxel in Japanese patients with newly diagnosed ovarian cancer

Use of Bevacizumab in Advanced Ovarian Cancer: Consensus from an Expert Panel Oncologists

Contact Info

Product

Resources

About